Research and Markets: Keeping up in the Fragmented Lymphoma Competitive Environment.

DUBLIN, Ireland -- Non-Hodgkins Lymphoma Drugs Treating is predicted to grow to almost $5 billion USD by 2008.

Research and Markets (http://www.researchandmarkets.com) has announced the addition of Keeping Up in the Fragmented Lymphoma Competitive Environment to their offering.

Keeping Up in the Fragmented Lymphoma Competitive Environment is a Highlight Report describing the latest advances in lymphoma treatment. This report provides material and analysis to facilitate the understanding and decision making in this fragmented and fast moving field. Lymphoma provides experimental possibilities for new compounds, allows an additional indication for already approved drugs, and generates large revenues for targeted treatments. An understanding of the lymphoma panorama, the sub-segmentation of this disease and the competition therein is fundamental for success.

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The lymphatic system helps filter out bacteria and is important in fighting disease. Every so often, the lymph vessels widen into lymph nodes. In lymphoma, some of the cells in the lymph system multiply uncontrollably. The type of cell that multiplies and how the cancer presents itself differentiates the subtypes of lymphoma. The two main groups of lymphoma in humans are Hodgkin's Disease (characterized by the growth of Reed-Sternberg cells) and the Non-Hodgkin's Lymphomas (NHL).

According to the American Cancer Society, 61 000 new cases of lymphoma are predicted in 2003 in the U.S. 53 400 of which will be Non-Hodgkin and 7 600 Hodgkin Lymphomas. Another 7300 Chronic Lymphatic Leukemias are predicted. The number of deaths are predicted to 24 700, 23 400, 1300, and 4 400 respectively.

The emerging non-Hodgkins lymphoma therapeutics market generated more that $1 billion USD in revenues in 2000. According to market studies the total revenue for drugs treating all stages of non-Hodgkins lymphoma could grow to almost $5 billion USD by 2008.

More than 100 companies are active in the process of developing and improving lymphoma therapies. Many of the biotechnology approaches, such as antibodies, tumor specific treatments, stem cell transplantations etc, seem to suit this diffuse form of cancer well.

Schering AG, the leader in the haematological oncology market, currently dominates new developments. It is believed unmet need remains in the market, but the limited prevalence limits sales potential to that of niche products. As there are few specialist treatment centers, marketing requirements are far from onerous, however, making the area a relatively profitable one.

NHL can be divided into two forms: aggressive and low-grade. The world prevalence is around 550,000 cases, of which 250,000 are low grade and 300,000 are aggressive.

The prevalence is currently increasing, mainly because of population ageing and an increase in HIV-related lymphomas.

Companies mentioned in this report include:

3M Pharmaceutical, AbGenomics Corp, Advanced Viral Research Corp, Alfacell, Amgen, AnorMED, Antigenics, Apollon, Aronex Pharmaceuticals, Aventis, Berlex Laboratories, BioCryst Pharmaceuticals, Bioenvision, Biomira, BioTransplant, Boston Life Sciences, Bristol-Myers Squibb, Cambridge Antibody Technology, Celgene, Celltech, Cell Therapeutics, CellGenix, Cerus, Chiron, Coley, Pharmaceutical Group, Corixa, Coulter Pharmaceutical, Crucell, Cytopia Pty, Diaclone, Dovetail Technologies, Dynavax Technologies, Elan, Eli Lilly, ENZO Biochem, eXegenics, Favrille, Fujisawa Pharmaceutical, Genentech, Genetics Institute, GeneTrol BioTherapeutics, Genitope Corp, Genmab, GenPat77, Pharmacogenetics, Genta , Geomed, Geron, Glaxo Smith Kline, Human Genome Sciences, IDEC Pharmaceuticals, ILEX Oncology, Immpheron, Immunex, Immunomedics, Inex Pharmaceuticals, Innate Pharma, Intermune, Intracel, Invivogen, Isis Pharmaceuticals, Kirin Brewery, Kucera Pharmaceutical, Kyowa Hakko Kogyo, Large Scale Biology Corp, Lifetime Pharmaceuticals, Ligand Pharmaceuticals, Lorus Therapeutics, Medac, Medarex, Micromet, Millenium Pharmaceuticals, Myriad Genetics, NeoRx, Novartis, Ortho Biotech, Peregrine Pharmaceuticals, Pharmacia & Upjohn, PharmaMar, Progenics Pharmaceuticals, Protein Design Labs, Regeneron Pharmaceuticals, Ribozyme Pharmaceuticals, Richter Gedeon, Roche, RxMed, Schering AG, Schering-Plough, SciClone, Seattle Genetics, Seikagaku, Seragen, SkyePharma, SLIL Biomedical, SpectrumPharm, Sumitomo Pharmaceuticals, Supergen, The Liposome Company, Theratechnologies, Tragen, Transgene, Tularik, Vasogen, Viacell, Vical, Viventia Biotech, Watson Pharmaceuticals, Wyeth, Xcyte Therapies, Yakult Honsha, Zenyaku Kogyo.

Drugs discussed in this Report

4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin

For more information visit http://www.researchandmarkets.com/reports/c2685